Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 04 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Budesonide delayed-release capsules. The capsules are indicated for treating mild to moderate active Crohn's disease in adults and children.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Zydus receives tentative approval from USFDA for Budesonide delayed release capsules, 4 mg".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases